GERN compared with PRLD: revenue, margins and what each company keeps, and the suppliers and customers both name

GERNGeron Corp

Mkt capRevenueRevenue

PRLDPrelude Therapeutics Inc

Mkt capRevenueRevenue

Compare

GERNGeron Corp

PRLDPrelude Therapeutics Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

GERNGeron Corp

0.89▼−5.85%· post 0.89

Mkt cap$574.6MRevenue$57MQ2 FY26Revenue$184MFY25

PRLDPrelude Therapeutics Inc

3.89▼−5.01%· post 3.89

ClosedOct 30 '26

Mkt cap$309.6MRevenue$6MQ2 FY26Revenue—

Compare

ClosedOct 30 '26

GERNGeron Corp

PRLDPrelude Therapeutics Inc

0.89▼−5.85%post 0.89

Price

3.89▼−5.01%post 3.89

$574.6M

Mkt cap

$309.6M

Q2 FY26$57M

Revenue

$6MQ2 FY26

FY25$184M

Revenue

—

GERN0.89▼−5.85%vsPRLD3.89▼−5.01%ClosedOct 30 '26

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

rebased to 0%

GERN, solidPRLD, dashed

Supply-chain overlap

Revenue flow

GERN: latest quarter is a loss; flow not drawable. PRLD: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only GERN 2

—Tanner Pharmaunlistedsupplier

—Royalty Pharma Development Fundingunlistedcustomer

Shared 0

No shared counterparties.

Only PRLD 3

INCYIncytecustomer

ABCLAbCellera Biologicscustomer

—Pathos AIunlistedcustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR